Genmab — Januar 2024
-
Analyse af aktie-casen Genmab: https://www.youtube.com/watch?v=i3_2joM-OHU&t=9s
-
4-1BB immunotherapy: advances and hurdles https://www.nature.com/articles/s12276-023-01136-4
-
Sundhedsinvestor om vigtigt år for dansk biotekkæmpe: Der kommer til at ske mange ting https://www.euroinvestor.dk/nyheder/sundhedsinvestor-om-vigtigt-aar-for-dansk-biotekkaempe-der-kommer-til-at?utm_medium=Social&utm_source=Facebook&fbclid=IwAR2qmLGszdx8NOtnhNk7K1F9o2crmWFYRNDVV8yhED8_g4epr3FOd2MnrLs#Echobox=1704351859
-
@legolas i går 20:21. Fuldstændig enig. Genmab har taget de tæsk som den skulle have pga. voldgiftssagen. Udfaldet over en uge vil være neutralt hvis den tabes, men ganske positiv hvis den vindes. Baseret udelukkende på en fornemmelse af markedets reaktion, så tror jeg at aktien stiger med minimum 10% på en vunden voldgift.
-
-
Interessant fra artiklen fra Finans at UBS forventer royalties på 330 mio. kr. i 2030 samlet fra Epkinly og Tivdak. Til sammenligning forventer Genmab Darzalex-royalties på mere end 11 mia. kr. i år.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

But a good example of how the narrative follows the price instead of vice versa; price goes down and stories need to be found to explain that..